Sunshine Biopharma- Warrants (15/02/2027) Profit Margin

Sunshine Biopharma- Warrants (15/02/2027) posts a profit margin of -16.5% as of June 2026. That compares with -17.35% in the prior-year period — up 4.9% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sunshine Biopharma- Warrants (15/02/2027)'s profit margin was -17.35%. The latest reading is -16.5% — a 4.9% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Sunshine Biopharma- Warrants (15/02/2027)'s -16.5% is lower that level. That is roughly 218.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Sunshine Biopharma- Warrants (15/02/2027)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -16.5% as of June 2026; use YoY and peer views to separate noise from signal.

Context for SBFMW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Sunshine Biopharma- Warrants (15/02/2027)'s other metric pages and overview cover the third.